Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 8944 results

  1. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  2. Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

    Discontinued Reference number: GID-TAG416

    Technology appraisal guidance
    Discontinued

  3. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  4. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued Reference number: GID-TAG300

    Technology appraisal guidance
    Discontinued

  5. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued Reference number: GID-TAG320

    Technology appraisal guidance
    Discontinued

  6. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued Reference number: GID-TAG321

    Technology appraisal guidance
    Discontinued

  7. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued

  8. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  9. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  10. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued Reference number: GID-TAG360

    Technology appraisal guidance
    Discontinued

  11. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  12. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  13. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  14. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

    Technology appraisal guidance
    Discontinued

  15. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued